INT197171

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2006
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 16
Disease Relevance 11.51
Pain Relevance 4.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Ppara) nucleus (Ppara) DNA binding (Ppara)
lipid metabolic process (Ppara)
Anatomy Link Frequency
liver 4
hepatocytes 2
Ppara (Mus musculus)
Pain Link Frequency Relevance Heat
fluoxetine 2 100.00 Very High Very High Very High
agonist 448 99.84 Very High Very High Very High
Inflammatory response 31 98.72 Very High Very High Very High
Central nervous system 106 98.68 Very High Very High Very High
Inflammation 250 97.92 Very High Very High Very High
fibrosis 23 91.52 High High
Multiple sclerosis 105 90.32 High High
chemokine 40 89.76 High High
metalloproteinase 19 88.68 High High
cINOD 39 86.16 High High
Disease Link Frequency Relevance Heat
Targeted Disruption 92 100.00 Very High Very High Very High
INFLAMMATION 298 98.72 Very High Very High Very High
Cancer 340 98.36 Very High Very High Very High
Toxicity 23 96.24 Very High Very High Very High
Death 34 95.28 Very High Very High Very High
Adverse Drug Reaction 6 95.16 Very High Very High Very High
Fatty Liver 127 92.56 High High
Diabetes Mellitus 107 91.96 High High
Metabolic Disorder 55 91.56 High High
Fibrosis 17 91.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Not only are hepatocytes abnormal and adversely affected from knockout of the PPAR?
Negative_regulation (affected) of PPAR Binding (knockout) of in hepatocytes associated with targeted disruption
1) Confidence 0.43 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1570084 Disease Relevance 0.82 Pain Relevance 0.08
However, this model disagrees with our result that PPAR?
Negative_regulation (disagrees) of PPAR Binding (result) of
2) Confidence 0.42 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1800345 Disease Relevance 1.53 Pain Relevance 0.30
of PPAR is altered and stabilized, and the PPAR-RXR heterodimer then recruits
Negative_regulation (recruits) of PPAR-RXR Binding (recruits) of
3) Confidence 0.40 Published 2008 Journal PPAR Research Section Body Doc Link PMC2430035 Disease Relevance 0 Pain Relevance 0
assays are based on direct interaction between PPAR and their specific ligands,
Negative_regulation (direct) of PPAR Binding (interaction) of
4) Confidence 0.40 Published 2008 Journal PPAR Research Section Body Doc Link PMC2430035 Disease Relevance 0.16 Pain Relevance 0.30
direct interaction of PPAR with proinflammatory transcription factors, most
Negative_regulation (direct) of PPAR Binding (interaction) of
5) Confidence 0.39 Published 2007 Journal PPAR Research Section Body Doc Link PMC1950239 Disease Relevance 1.12 Pain Relevance 0.56
, the PPAR ligands typically prevented or
Negative_regulation (prevented) of PPAR Binding (ligands) of
6) Confidence 0.39 Published 2007 Journal PPAR Research Section Body Doc Link PMC1950239 Disease Relevance 0.62 Pain Relevance 0.46
GW501516 exhibit an association between PDK1 and PPAR?
Negative_regulation (exhibit) of PPAR Binding (association) of
7) Confidence 0.38 Published 2008 Journal PPAR Research Section Body Doc Link PMC2430014 Disease Relevance 1.22 Pain Relevance 0.39
metabolism, however, these receptors, especially PPAR?
Negative_regulation (metabolism) of PPAR Binding (receptors) of
8) Confidence 0.33 Published 2008 Journal PPAR Research Section Body Doc Link PMC2465016 Disease Relevance 0.61 Pain Relevance 0.17
CYP2C9 is the second most abundant P450 expressed in human liver and is responsible for the metabolism of S-warfarin, Tamoxifen, fluoxetine, losartan, and the antidiabetic PPAR?
Negative_regulation (losartan) of PPAR Binding (metabolism) of in liver associated with fluoxetine
9) Confidence 0.31 Published 2009 Journal PPAR Research Section Body Doc Link PMC2840373 Disease Relevance 1.74 Pain Relevance 0.33
CYP2C9 is the second most abundant P450 expressed in human liver and is responsible for the metabolism of S-warfarin, Tamoxifen, fluoxetine, losartan, and the antidiabetic PPAR?
Negative_regulation (fluoxetine) of PPAR Binding (metabolism) of in liver associated with fluoxetine
10) Confidence 0.31 Published 2009 Journal PPAR Research Section Body Doc Link PMC2840373 Disease Relevance 1.74 Pain Relevance 0.33
suppress translation initiation in a PPAR?
Negative_regulation (suppress) of PPAR Binding (initiation) of
11) Confidence 0.28 Published 2008 Journal PPAR Research Section Body Doc Link PMC2396401 Disease Relevance 0.08 Pain Relevance 0
suppressed in the presence of ligands following formation of PPAR-?
Negative_regulation (suppressed) of PPAR Binding (formation) of
12) Confidence 0.24 Published 2008 Journal PPAR Research Section Body Doc Link PMC2441778 Disease Relevance 0.18 Pain Relevance 0.10
Physical interaction with PPAR/RXR inhibits binding of these transcription
Negative_regulation (inhibits) of PPAR Binding (binding) of
13) Confidence 0.24 Published 2008 Journal PPAR Research Section Body Doc Link PMC2441778 Disease Relevance 0 Pain Relevance 0.08
to evaluate the efficacy of these PPAR-?
Negative_regulation (evaluate) of PPAR Binding (efficacy) of
14) Confidence 0.23 Published 2008 Journal PPAR Research Section Body Doc Link PMC2441778 Disease Relevance 0.86 Pain Relevance 0.72
developed on the basis of their activity on human PPAR-?
Negative_regulation (developed) of PPAR Binding (activity) of
15) Confidence 0.18 Published 2008 Journal PPAR Research Section Body Doc Link PMC2367430 Disease Relevance 0.09 Pain Relevance 0.58
This is induced by a reversible interaction of PPAR?
Negative_regulation (reversible) of PPAR Binding (interaction) of
16) Confidence 0.09 Published 2008 Journal PPAR Research Section Body Doc Link PMC2440494 Disease Relevance 0.73 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox